M. Reck, D. Rodríguez-abreu, and A. Robinson, Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1833, 2016.
DOI : 10.1056/NEJMoa1606774

C. Robert, G. Long, and B. Brady, Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-330, 2015.
DOI : 10.1056/NEJMoa1412082

URL : https://hal.archives-ouvertes.fr/cea-01886121

C. Robert, J. Schachter, and G. Long, Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2532, 2015.
DOI : 10.1056/NEJMoa1503093

S. Ansell, A. Lesokhin, and I. Borrello, PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma, New England Journal of Medicine, vol.372, issue.4, pp.311-319, 2015.
DOI : 10.1056/NEJMoa1411087

J. Rosenberg, J. Hoffman-censits, and T. Powles, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, The Lancet, vol.387, issue.10031, pp.1909-1920, 2016.
DOI : 10.1016/S0140-6736(16)00561-4

R. Ferris, G. Blumenschein, . Jr, and J. Fayette, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.375, issue.19, pp.1856-1867, 2016.
DOI : 10.1056/NEJMoa1602252

L. Fehrenbacher, A. Spira, and M. Ballinger, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet, vol.387, issue.10030, pp.1837-1846, 2016.
DOI : 10.1016/S0140-6736(16)00587-0

R. Herbst, P. Baas, and D. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet, vol.387, issue.10027, pp.1540-1550, 2016.
DOI : 10.1016/S0140-6736(15)01281-7

J. Brahmer, K. Reckamp, and P. Baas, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-135, 2015.
DOI : 10.1056/NEJMoa1504627

M. Nishino, N. Ramaiya, and M. Awad, PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course, Clinical Cancer Research, vol.22, issue.24, pp.6051-6060, 2016.
DOI : 10.1158/1078-0432.CCR-16-1320

J. Naidoo, X. Wang, and K. Woo, Pneumonitis in Patients Treated With Anti???Programmed Death-1/Programmed Death Ligand 1 Therapy, Journal of Clinical Oncology, vol.35, issue.7, pp.709-717, 2017.
DOI : 10.1200/JCO.2016.68.2005

P. Camus, A. Fanton, and P. Bonniaud, Interstitial Lung Disease Induced by Drugs and Radiation, Respiration, vol.71, issue.4, pp.301-326, 2004.
DOI : 10.1159/000079633

F. Sakai, T. Johkoh, and M. Kusumoto, Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings, International Journal of Clinical Oncology, vol.11, issue.6, pp.542-550, 2012.
DOI : 10.1097/00004728-198701000-00034

, 00050-2017 Terminology Criteria for Adverse Events (CTCAE) Version 4.0. NIH Publication No 09-5410, 2009.

C. Mueller-mang, C. Grosse, and K. Schmid, What Every Radiologist Should Know about Idiopathic Interstitial Pneumonias, RadioGraphics, vol.27, issue.3, pp.595-615, 2007.
DOI : 10.1148/rg.273065130

W. Travis, U. Costabel, and D. Hansell, An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias, American Journal of Respiratory and Critical Care Medicine, vol.39, issue.1, pp.733-748, 2013.
DOI : 10.1136/thx.2008.102814

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009.
DOI : 10.1016/j.ejca.2008.10.026

H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1639, 2015.
DOI : 10.1056/NEJMoa1507643

URL : http://europepmc.org/articles/pmc5705936?pdf=render

R. Herbst, P. Baas, and D. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet, vol.387, issue.10027, pp.1540-1550, 2016.
DOI : 10.1016/S0140-6736(15)01281-7

M. Nishino, A. Giobbie-hurder, and H. Hatabu, Incidence of Programmed Cell Death 1 Inhibitor???Related Pneumonitis in Patients With Advanced Cancer, JAMA Oncology, vol.2, issue.12, pp.1607-1616, 2016.
DOI : 10.1001/jamaoncol.2016.2453

, 21

V. Liu, D. White, and M. Zakowski, Pulmonary Toxicity Associated With Erlotinib, Chest, vol.132, issue.3, pp.1042-1044, 2007.
DOI : 10.1378/chest.07-0050

J. Konishi, K. Yamazaki, and I. Kinoshita, Analysis of the response and toxicity to gefitinib of non-small cell lung cancer, Anticancer Res, vol.25, pp.435-441, 2005.

C. Grande, M. Villanueva, and G. Huidobro, Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment, Clinical and Translational Oncology, vol.29, issue.9, pp.578-581, 2007.
DOI : 10.4046/trd.2004.57.3.257

D. Roychowdhury, C. Cassidy, and P. Peterson, A report on serious pulmonary toxicity associated with gemcitabine-based therapy, Investigational New Drugs, vol.20, issue.3, pp.311-315, 2002.
DOI : 10.1023/A:1016214032272

A. Hochstrasser, G. Benz, and M. Joerger, Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?, Chemotherapy, vol.256, issue.1, pp.84-88, 2012.
DOI : 10.1016/j.tox.2008.11.016

Y. Loriot, C. Ferte, and C. Gomez-roca, Pemetrexed-Induced Pneumonitis: A Case Report, Clinical Lung Cancer, vol.10, issue.5, pp.364-366, 2009.
DOI : 10.3816/CLC.2009.n.050

P. Créquit, M. Wislez, F. Feith, and J. , Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review, Journal of Thoracic Oncology, vol.10, issue.8, pp.1148-1155, 2015.
DOI : 10.1097/JTO.0000000000000577

M. Nishino, L. Sholl, and F. Hodi, Anti???PD-1???Related Pneumonitis during Cancer Immunotherapy, New England Journal of Medicine, vol.373, issue.3, pp.288-290, 2015.
DOI : 10.1056/NEJMc1505197

K. Nakashima, T. Naito, and S. Omori, Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma, Journal of Thoracic Oncology, vol.11, issue.3, pp.432-433, 2016.
DOI : 10.1016/j.jtho.2015.10.004

V. Gounant, S. Brosseau, and C. Naltet, Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma, Lung Cancer, vol.99, pp.162-165, 2016.
DOI : 10.1016/j.lungcan.2016.07.010

C. Chiang, Y. Chen, and M. Wu, Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer, Journal of the Chinese Medical Association, vol.79, issue.5, pp.248-255, 2016.
DOI : 10.1016/j.jcma.2016.01.008

T. Lynch, I. Bondarenko, and A. Luft, Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non???Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study, Journal of Clinical Oncology, vol.30, issue.17, pp.2046-2054, 2012.
DOI : 10.1200/JCO.2011.38.4032

A. Inoue, H. Kunitoh, and I. Sekine, Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis, International Journal of Radiation Oncology*Biology*Physics, vol.49, issue.3, pp.649-655, 2001.
DOI : 10.1016/S0360-3016(00)00783-5

I. Barjaktarevic, N. Qadir, and A. Suri, Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma, Chest, vol.143, issue.3, pp.858-861, 2013.
DOI : 10.1378/chest.12-1467

N. Satake, S. Nagai, and A. Kawatani, Density of phenotypic markers on BAL T-lymphocytes in hypersensitivity pneumonitis, pulmonary sarcoidosis and bronchiolitis obliterans with organizing pneumonia, Eur Respir J, vol.6, pp.477-482, 1993.

G. Berthod, R. Lazor, and I. Letovanec, Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab, Journal of Clinical Oncology, vol.30, issue.17, pp.156-159, 2012.
DOI : 10.1200/JCO.2011.39.3298

D. Kim, J. Je, and S. Kim, Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis, Archives of Dermatological Research, vol.94, issue.6, pp.531-538, 2015.
DOI : 10.1016/j.imlet.2004.05.007

S. Tabchi, C. Messier, and N. Blais, Immune-mediated respiratory adverse events of checkpoint inhibitors, Current Opinion in Oncology, vol.28, issue.4, pp.269-277, 2016.
DOI : 10.1097/CCO.0000000000000291

Y. Bronstein, C. Ng, and P. Hwu, Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti???CTLA-4 Antibody Therapy, American Journal of Roentgenology, vol.197, issue.6, pp.992-1000, 2011.
DOI : 10.2214/AJR.10.6198

J. Osorio, A. Ni, and J. Chaft, Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer, Annals of Oncology, vol.28, pp.583-589, 2017.
DOI : 10.1093/annonc/mdw640

URL : http://europepmc.org/articles/pmc5834017?pdf=render